Published in Am J Respir Crit Care Med on May 08, 2003
The Role of Physical Activity and Diet Within Pulmonary Sarcoidosis | NCT03336736
Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax (2005) 1.71
Advances in the diagnosis and treatment of sarcoidosis. F1000Prime Rep (2014) 0.96
Sarcoidosis: an update for the primary care physician. MedGenMed (2004) 0.85
Sarcoidosis: sex-dependent variations in presentation and management. J Ophthalmol (2014) 0.84
Reliability and convergent validity of the cutaneous sarcoidosis activity and morphology instrument for assessing cutaneous sarcoidosis. JAMA Dermatol (2013) 0.81
Distance saturation product predicts health-related quality of life among sarcoidosis patients. Health Qual Life Outcomes (2012) 0.77
The effect of corticosteroids on quality of life in a sarcoidosis clinic: the results of a propensity analysis. Respir Med (2015) 0.77
Quality of life in sarcoidosis: comparing the impact of ocular and non-ocular involvement of the disease. Ophthalmic Epidemiol (2010) 0.76
Validation of the Japanese version of the Sarcoidosis Health Questionnaire: a cross-sectional study. Health Qual Life Outcomes (2011) 0.75
Administering the Sarcoidosis Health Questionnaire to sarcoidosis patients in Serbia. J Bras Pneumol (2016) 0.75
Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med (2006) 4.20
A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med (2004) 3.33
Sarcoidosis: a comprehensive review and update for the dermatologist: part I. Cutaneous disease. J Am Acad Dermatol (2012) 2.71
Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis (2003) 2.49
Endobronchial ultrasound for the diagnosis of pulmonary sarcoidosis. Chest (2007) 2.22
A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med (2010) 1.98
Cardiac sarcoidosis. Am Heart J (2008) 1.89
Bronchodilator reversibility in COPD. Chest (2011) 1.89
The treatment of lupus pernio: results of 116 treatment courses in 54 patients. Chest (2008) 1.78
MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting. Clin Infect Dis (2014) 1.78
CXCR2 Antagonist MK-7123. A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med (2015) 1.70
The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2007) 1.70
Cutaneous sarcoidosis. Semin Respir Crit Care Med (2010) 1.69
Minimal clinically important differences in the six-minute walk test and the incremental shuttle walking test. COPD (2005) 1.68
Reconsidering sex-based stereotypes of COPD. Prim Care Respir J (2011) 1.66
Pleural effusions in a series of 181 outpatients with sarcoidosis. Chest (2006) 1.50
Neurosarcoidosis: Clinical manifestations, diagnosis and treatment. Presse Med (2012) 1.44
Treatment of sarcoidosis with infliximab. Chest (2005) 1.43
Chronic cutaneous lesions of sarcoidosis. Clin Dermatol (2007) 1.41
Predicting risk of airflow obstruction in primary care: Validation of the lung function questionnaire (LFQ). Respir Med (2010) 1.33
Neurosarcoidosis: presentations and management. Neurologist (2010) 1.33
Organizing pneumonia. Am J Med Sci (2008) 1.32
Do symptoms predict COPD in smokers? Chest (2010) 1.22
Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis. Respir Res (2011) 1.19
Cellular responses to mycobacterial antigens are present in bronchoalveolar lavage fluid used in the diagnosis of sarcoidosis. Infect Immun (2009) 1.19
The future of chronic obstructive pulmonary disease treatment--difficulties of and barriers to drug development. Lancet (2011) 1.19
Ambient air pollution particles and the acute exacerbation of chronic obstructive pulmonary disease. Inhal Toxicol (2008) 1.19
A sarcoidosis genetic linkage consortium: the sarcoidosis genetic analysis (SAGA) study. Sarcoidosis Vasc Diffuse Lung Dis (2005) 1.18
The etiologic agent of sarcoidosis: what if there isn't one? Chest (2003) 1.17
Spinal cord neurosarcoidosis. Am J Med Sci (2014) 1.17
The spectrum of biopsy sites for the diagnosis of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis (2005) 1.16
Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis. Respir Res (2013) 1.12
Sarcoidosis associated with an elevated serum CA 125 level: description of a case and a review of the literature. Am J Med Sci (2007) 1.11
Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respir Res (2011) 1.09
Health-related quality of life of persons with sarcoidosis. Chest (2004) 1.08
Pulmonary and psychosocial findings at enrollment in the ACCESS study. Sarcoidosis Vasc Diffuse Lung Dis (2005) 1.07
Development of the Lung Function Questionnaire (LFQ) to identify airflow obstruction. Int J Chron Obstruct Pulmon Dis (2010) 1.07
Chronic obstructive pulmonary disease and asthma-patient characteristics and health impairment. COPD (2013) 1.06
Treatment of corticosteroid-resistant neurosarcoidosis with a short-course cyclophosphamide regimen. Chest (2003) 1.06
Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. Respir Med (2010) 1.05
Disturbed homeostasis and multiple signaling defects in the peripheral blood B-cell compartment of patients with severe chronic sarcoidosis. Clin Vaccine Immunol (2011) 1.03
Racial and ethnic disparities in sarcoidosis: from genetics to socioeconomics. Clin Chest Med (2006) 1.02
Prevalence of airway obstruction assessed by lung function questionnaire. Mayo Clin Proc (2011) 1.01
Isolated neurosarcoidosis: case series in 2 sarcoidosis centers. Neurologist (2012) 0.99
Effects of sleep apnea on nocturnal free fatty acids in subjects with heart failure. Sleep (2011) 0.98
Nontuberculous mycobacteria in women, young and old. Clin Chest Med (2002) 0.95
A new tool to assess sarcoidosis severity. Chest (2006) 0.95
Inflammatory profile and response to anti-tumor necrosis factor therapy in patients with chronic pulmonary sarcoidosis. Clin Vaccine Immunol (2011) 0.95
Successful treatment of lupus pernio with adalimumab. Arch Dermatol (2011) 0.94
Current and emerging pharmacological treatments for sarcoidosis: a review. Drug Des Devel Ther (2013) 0.94
Neurological deficits during treatment with tumor necrosis factor-alpha antagonists. Am J Med Sci (2011) 0.93
Effect of salmeterol on mucociliary and cough clearance in chronic bronchitis. Pulm Pharmacol Ther (2005) 0.93
Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators. Proc Am Thorac Soc (2007) 0.93
Sarcoidosis. Med Clin North Am (2005) 0.91
Allergic bronchopulmonary aspergillosis. Clin Chest Med (2012) 0.91
Neurosarcoidosis. Curr Treat Options Neurol (2013) 0.90
Differences in symptom severity and health status impairment between patients with pulmonary and pulmonary plus extrapulmonary sarcoidosis. Respir Med (2008) 0.89
Shortness of Breath with Daily Activities questionnaire: validation and responder thresholds in patients with chronic obstructive pulmonary disease. BMJ Open (2013) 0.88
Thalidomide for chronic sarcoidosis. Chest (2002) 0.88
Low levels of NF-κB/p65 mark anergic CD4+ T cells and correlate with disease severity in sarcoidosis. Clin Vaccine Immunol (2010) 0.88
Sarcoidosis presenting as bilateral vocal cord paralysis from bilateral compression of the recurrent laryngeal nerves from thoracic adenopathy. J Voice (2008) 0.87
Clinical trial design in chronic obstructive pulmonary disease: current perspectives and considerations with regard to blinding of tiotropium. Respir Res (2012) 0.87
Job and industry classifications associated with sarcoidosis in A Case-Control Etiologic Study of Sarcoidosis (ACCESS). J Occup Environ Med (2005) 0.87
Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations. Am J Med Sci (2010) 0.86
Patient-reported outcome measures for sleep disorders and related problems: clinical and research applications. Chest (2013) 0.86
Development and validation of the Chronic Obstructive Pulmonary Disease Assessment Questionnaire (COPD-AQ). Prim Care Respir J (2009) 0.86
Pneumocystis jerovecii pneumonia in a patient with untreated chronic lymphocytic leukaemia: a novel case and postulations concerning the mechanism. BMJ Case Rep (2013) 0.85
Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis (2002) 0.84
A modern series of percutaneous intracavitary instillation of amphotericin B for the treatment of severe hemoptysis from pulmonary aspergilloma. Chest (2013) 0.84
Impact of systemic corticosteroids on healthcare utilization in patients with sarcoidosis. Am J Med Sci (2011) 0.84
Clinical manifestations, radiographic findings, treatment options, and outcome in sarcoidosis patients with upper respiratory tract involvement. South Med J (2010) 0.83
Efficacy and safety of apremilast in chronic cutaneous sarcoidosis. Arch Dermatol (2011) 0.83
Staple metalloptysis after lung resection for mycetoma: a case report and a review of the literature. Am J Med Sci (2008) 0.83
Chronic facial sarcoidosis including lupus pernio: clinical description and proposed scoring systems. Am J Clin Dermatol (2008) 0.83
Population-based burden of COPD-related visits in the ED: return ED visits, hospital admissions, and comorbidity risks. Chest (2013) 0.83
Relationship of environmental exposures to the clinical phenotype of sarcoidosis. Chest (2005) 0.83
Pleural effusion caused by trapped lung. South Med J (2003) 0.83
Health-related quality of life and chronic obstructive pulmonary disease in North Carolina. N Am J Med Sci (2010) 0.82
Changes in chest roentgenogram of sarcoidosis patients during a clinical trial of infliximab therapy: comparison of different methods of evaluation. Chest (2009) 0.82
Acute pulmonary exacerbations of sarcoidosis. Chest (2012) 0.82
Clinical outcomes in sarcoidosis after cessation of infliximab treatment. Respirology (2009) 0.81
A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease. Expert Opin Pharmacother (2015) 0.81
Valproic acid-induced eosinophilic pleural effusion: a case report and review of the literature. Am J Med Sci (2007) 0.81
Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial. Sarcoidosis Vasc Diffuse Lung Dis (2016) 0.81
Improved sputum expectoration following a single dose of INS316 in patients with chronic bronchitis. Chest (2002) 0.80
Bird-years as well as pack-years. Chest (2004) 0.80
Quality of life evaluation in sarcoidosis: current status and future directions. Curr Opin Pulm Med (2008) 0.80
Rapid development of sarcoid tenosynovitis. J Clin Rheumatol (2011) 0.79
Relapses of sarcoidosis: what are they and can we predict who will get them? Eur Respir J (2014) 0.79
Multi-center study: the biochemical efficacy, safety and tolerability of a new alpha1-proteinase inhibitor, Zemaira. COPD (2006) 0.78
Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD. Semin Respir Crit Care Med (2010) 0.78
Optimum bronchodilator combinations in chronic obstructive pulmonary disease: what is the current evidence? Drugs (2012) 0.78
Sarcoidosis: a comprehensive review and update for the dermatologist: part II. Extracutaneous disease. J Am Acad Dermatol (2012) 0.78
Small fiber neuropathy in sarcoidosis: Something beneath the surface. Respir Med (2010) 0.78